info@marketresearchfuture.com   📞 +1 (855) 661-4441(US)   📞 +44 1720 412 167(UK)   📞 +91 2269738890(APAC)
Certified Global Research Member
Isomar 1 Iso 1
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Bronchodilators Market Research Report Information By Drug Type (Adrenergic drugs, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs), By Disease (Asthma, COPD, Others), By Mode of Action (Short-Acting Bronchodilators, Long-Acting Bronchodilators) and By Route of Administration (Oral, Parenteral) – Forecast to 2032


ID: MRFR/HC/6981-HCR | 111 Pages | Author: Rahul Gotadki| August 2025

Bronchodilators Market Overview

Bronchodilators Market Size was valued at USD 33.81 Billion in 2023. The Global Bronchodilators industry is projected to grow from USD 35.57 Billion in 2024 to USD 53.44 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.78% during the forecast period (2024 - 2032).

There has been a rise in the prevalence of COPD and asthma and a high level of technological improvement in bronchodilators in the past few years, which is fueling the global market growth. Also, as bronchodilators are used rigorously for all respiratory disorders, companies are investing in this market.

Bronchodilators Market Overview

Increase in prevalence of pulmonary disorders Growing technological advancements. The rise in disposable income. Increasing geriatric population Growing government initiatives for creating awareness among the general population. Increasing mergers and acquisitions by prominent players in the market. For instance, in April 2019, Cipla Technologies entered into an agreement with Pulmatrix Inc. to co-develop a formulation for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. Growing funding by government organizations

Market Restraints

    • Side effects associated with bronchodilators
    • Government regulations related to the safety & efficacy of the bronchodilators

Bronchodilators Market Segment Insights

Bronchodilators Drug Type Insights

    • Adrenergic drugs: Expected to hold the largest share, adrenergic drugs are the most potent bronchodilators approved for clinical use in asthma and obstructive lung disease. Adrenergic bronchodilators dilate bronchial airways by relaxing the muscles that surround the airways.

    • Anticholinergics: The "anticholinergic" effect of anticholinergic bronchodilators blocks the effect of cholinergic nerves, causing the muscles to relax and airways to dilate.

    • Phosphodiesterase Inhibitor: Phosphodiesterase inhibitors have long been recognized as being effective drugs for the treatment of asthma and chronic obstructive pulmonary disease (COPD). They possess both anti-inflammatory and bronchodilator activity in the same molecule.

    • Combination Drugs: These combination drugs are used if COPD and asthma are not controlled with monotherapy. These combinations involve two long-acting bronchodilators with differing modes of action.

Bronchodilators Disease Insights

    • Asthma: Bronchodilators help in relieving asthma by relaxing the muscle bands that tighten around the airways due to which the breathing improves. Bronchodilators also help clear mucus from the lungs. The large market share for asthma is owing to the rising number of patients affected with asthma around the globe.

    • COPD: Bronchodilators are the primary treatment for chronic obstructive pulmonary disease (COPD) as they help to alleviate bronchial obstruction and airflow limitation, reduce hyperinflation, and improve emptying of the lung and exercise performance. Due to these reasons, inhaled bronchodilators are the mainstay of the current management of all stages of COPD.

    • Others: The other segment includes other respiratory disorders and allergic reactions that cause breathing difficulty.

Bronchodilators Mode of Action Insights

    • Short-Acting Bronchodilators: This is expected to be the largest segment, owing to its ability to provide quick relief from sudden, unexpected attacks of breathlessness and can be used on a daily basis.

    • Long-Acting Bronchodilators: These type of bronchodilators helps in controlling the symptoms of asthma by opening the air passage. A major disadvantage of long-acting bronchodilators is that it increases the risk of asthma death. Hence, it should be used only as an added treatment for individuals or patients who use corticosteroids.

Bronchodilators Route of Administration Insights

    • Oral: Oral route of administration offers advantages such as ease and simplicity of administration along with control of the delivered dose.

    • Parenteral: This route of administration includes subcutaneous, intramuscular, and intravenous routes. The advantages of this route of administration include the complete bioavailability of the drug and rapid onset of action. However, there are certain disadvantages such as patient discomfort, the need for sterile conditions, and potential risks to health care practitioners from blood-borne pathogens.

Bronchodilators Regional Insights

    • Americas: It is the largest regional market due to rising cases of asthma, increased awareness levels regarding treatment options, and the rising adoption of inhaled therapeutics.

    • Europe: The growing presence of the developed pharmaceutical industry and the significant demand for asthma-related therapeutics is driving the growth of the bronchodilators market in the Europe region. Additionally, rising cases of COPD and asthma is driving the market growth. An estimated 1.2 million people are living with diagnosed COPD, according to the British Lung Foundation. Moreover, around 2% of the whole population and 4.5% of all people aged over 40 live with diagnosed COPD in the UK.

    • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global bronchodilators market. This region is seeing a surge in the number of people who have asthma and other respiratory disorders.

    • Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.

Bronchodilators Market Top Key Players

    • Novartis AG (Switzerland)
    • Merck & Co., Inc. (US)
    • Abbott Laboratories (US)
    • Boehringer Ingelheim GmbH (Germany)
    • AstraZeneca plc (UK)
    • Hoffmann LA-Roche AG (Switzerland)
    • Teva Pharmaceutical (Israel)
    • Pfizer Inc. (US)

Bronchodilators Market Trends

The increasing initiatives by public and private companies boost market growth. The growing number of clearances and product launches by key players in the market are likely to act as a promising factor for growth in the near future.

Bronchodilators Market Industry Developments

  • Q2 2024: GSK receives FDA approval for Trelegy Ellipta expanded indication in asthma GlaxoSmithKline announced that the U.S. FDA approved an expanded indication for its inhaled bronchodilator Trelegy Ellipta, allowing its use in a broader population of asthma patients.
  • Q1 2024: AstraZeneca’s Airsupra receives FDA approval for asthma maintenance AstraZeneca and Avillion announced that the FDA approved Airsupra, a combination bronchodilator, for the maintenance treatment of asthma in patients aged 18 years and older.
  • Q2 2024: Novartis launches Enerzair Breezhaler in Japan for COPD Novartis announced the commercial launch of Enerzair Breezhaler, a triple-combination bronchodilator, in Japan for the treatment of chronic obstructive pulmonary disease (COPD).
  • Q1 2024: Boehringer Ingelheim opens new respiratory drug manufacturing facility in Germany Boehringer Ingelheim inaugurated a new manufacturing facility dedicated to the production of inhaled bronchodilators and other respiratory medicines in Biberach, Germany.
  • Q2 2024: Pfizer announces partnership with Propeller Health to develop digital-connected bronchodilator inhalers Pfizer entered a strategic partnership with Propeller Health to co-develop digital inhalers for bronchodilator medications, aiming to improve adherence and outcomes in asthma and COPD patients.
  • Q2 2024: Sanofi receives EMA approval for new bronchodilator combination therapy for COPD Sanofi announced that the European Medicines Agency approved its new fixed-dose combination bronchodilator for the maintenance treatment of COPD in adults.
  • Q1 2025: Vectura Group secures contract to supply generic inhaled bronchodilator to NHS Vectura Group announced it has won a multi-year contract to supply its generic inhaled bronchodilator to the UK National Health Service, expanding access to affordable respiratory care.
  • Q2 2024: Teva launches generic version of ProAir HFA inhaler in the US Teva announced the US launch of its FDA-approved generic albuterol sulfate inhaler, expanding access to a widely used bronchodilator for asthma and COPD.
  • Q1 2024: AstraZeneca acquires respiratory biotech startup developing novel bronchodilator AstraZeneca completed the acquisition of a privately held biotech company focused on next-generation bronchodilator therapies for asthma and COPD.
  • Q2 2025: GlaxoSmithKline appoints new head of respiratory business unit GlaxoSmithKline announced the appointment of a new executive to lead its global respiratory business, which includes its portfolio of bronchodilator products.
  • Q1 2025: Novartis receives China NMPA approval for Ultibro Breezhaler in COPD Novartis announced that China's National Medical Products Administration approved Ultibro Breezhaler, a dual bronchodilator, for the treatment of COPD.
  • Q2 2024: Sanofi and Regeneron expand partnership to develop next-generation inhaled bronchodilators Sanofi and Regeneron announced an expanded collaboration to co-develop a pipeline of next-generation inhaled bronchodilators targeting severe asthma and COPD.
Report Attribute/Metric Details
Market Size 2023 33.81 (USD Billion)
Market Size 2024 35.57 (USD Billion)
Market Size 2032 53.44 (USD Billion)
Compound Annual Growth Rate (CAGR) 5.78 % (2024 - 2032)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year 2023
Market Forecast Period 2024 - 2032
Historical Data 2019 - 2023
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline (UK), Novartis AG (Switzerland), Merck & Co., Inc. (US), Abbott Laboratories (US), Boehringer Ingelheim GmbH (Germany), AstraZeneca plc (UK), Hoffmann LA-Roche AG (Switzerland), Teva Pharmaceutical (Israel), Pfizer Inc. (US)
  Key Market Opportunities   Growing technological advancements and Growing funding by government organizations
  Key Market Drivers Increase in prevalence of pulmonary disorders, The rise in disposable income and Increasing geriatric population


Frequently Asked Questions (FAQ):

The valuation of the global Bronchodilators market is estimated to reach USD 53.44 Billion during the forecast period.

The global Bronchodilators market is projected to grow at approximately 5.78% CAGR during the forecast period.

The rise in disposable income Increasing geriatric population

North America holds the largest share in the global Bronchodilators market, followed by Europe and the Asia Pacific, respectively.

Novartis AG (Switzerland), GlaxoSmithKline (UK), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Abbott Laboratories (US), AstraZeneca plc (UK), Teva Pharmaceutical (Israel), Hoffmann LA-Roche AG (Switzerland), and Pfizer Inc. (US), are some of the major players operating in the Bronchodilators market.

Comments

Leading companies partner with us for data-driven Insights.

clients

Kindly complete the form below to receive a free sample of this Report

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
report-img